Public warned 'do not approach' missing man last seen leaving Newham hospital
The public was been warned not to approach a missing man last seen leaving a hospital in Newham. Anyone who sees him is being asked to call 999 at the first instance.
Kenneth, who uses a wheelchair, was last spotted leaving Newham University Hospital, in Plaistow, at 6.20pm yesterday (Monday, May 26). He was last seen wearing a grey Lonsdale hoodie, black jeans and jacket.
Police have warned the public not to approach him and instead to call 999 if they spot him.
READ MORE: Boy, 17, may have life-changing injuries after Rainham stabbing with attacker on the loose
READ MORE: Victim broke spine in balcony jump after knifepoint torture and rape threat over £15k savings
#MISSING | Kenneth was last seen leaving Newham University Hospital in Plaistow at 6.20pm on 26 May. He was wearing a grey Lonsdale hoodie, black jeans and jacket. He uses a wheelchair.If you see him, please do not approach him, but call 999 quoting CAD 252/26May. pic.twitter.com/04HITSRQIu
— Newham MPS | North East BCU (@MPSNewham) May 27, 2025
A spokesperson for Newham MPS posted to X: "Kenneth was last seen leaving Newham University Hospital in Plaistow at 6.20pm on 26 May. He was wearing a grey Lonsdale hoodie, black jeans and jacket.
"He uses a wheelchair. If you see him, please do not approach him, but call 999 quoting CAD 252/26May."
Got a story? Please get in touch at katherine.gray@reachplc.com
Looking for more from MyLondon? Subscribe to our daily newsletters here for the latest and greatest updates from across London.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Hemostemix Closes Private Placement of $469,366
Calgary, Alberta--(Newsfile Corp. - June 17, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VF0) ("Hemostemix" or the "Company") announces the closing of a non brokered private placement with in the amount of CAD $469,366 by the issuance of 3,911,385 Common Shares at CAD $0.12 each, subject to the approval of the TSXV Exchange. All securities issued in connection with the Offering will be subject to a four-month hold period from the closing date under applicable Canadian securities laws, in addition to such other restrictions as may apply under applicable securities laws of jurisdictions outside Canada. Per Policy 4.1. the Subscriber is arm's length to the Company and is not a Related Party to the Company at the time of disclosure. The use of proceeds will be allocated to general working capital purposes, supporting the Company's ongoing operational expenses and business development activities. The Company confirms that there is no material fact or material change about the Company that has not been generally disclosed. ABOUT HEMOSTEMIX Hemostemix is an autologous stem cell therapy platform company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the Company has developed, patented, is scaling and selling autologous (patient's own) blood-based stem cell therapies that include angiogenic cell precursors (ACP-01). Hemostemix has completed seven clinical studies of 318 subjects and published its results in nine peer reviewed publications. ACP-01 is safe, clinically relevant and statistically significant as a treatment for peripheral arterial disease, chronic limb threatening ischemia, non ischemic dilated cardiomyopathy, ischemic cardiomyopathy, congestive heart failure, and angina. Hemostemix completed its Phase II clinical trial for chronic limb threatening ischemia and published its results in the Journal of Biomedical Research & Environmental Science. As compared to a five year mortality rate of 60% in the CLTI patient population, UBC and U of T reported to the 41st meeting of vascular surgeons: 0% mortality, cessation of pain, wound healing in 83% of patients followed for up to 4.5 years, as a midpoint result. For more information, please visit For further information, please contact: Thomas Smeenk, President, CEO & Co-Founder EM: tsmeenk@ PH: 905-580-4170 Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined under the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release. Forward-Looking Information: This news release contains "forward-looking information" within the meaning of applicable Canadian securities legislation. All statements, other than statements of historical fact, included herein are forward-looking information. In particular, this news release contains forward-looking information in relation to sales of its lead product ACP-01, the commercialization of ACP-01 via the sale of compassionate treatments under Special Access Programs. There can be no assurance that such forward-looking information will prove to be accurate. Actual results and future events could differ materially from those anticipated in such forward-looking information. This forward-looking information reflects Hemostemix's current beliefs and is based on information currently available to Hemostemix and on assumptions Hemostemix believes are reasonable. These assumptions include, but are not limited to: the underlying value of Hemostemix and its Common Shares; the successful resolution of any litigation that Hemostemix is pursuing or defending (the "Litigation"); the results of ACP-01 research, trials, studies and analyses, including the analysis being equivalent to or better than previous research, trials or studies; the receipt of all required regulatory approvals for research, trials or studies; the level of activity, market acceptance and market trends in the healthcare sector; the economy generally; consumer interest in Hemostemix's services and products; competition and Hemostemix's competitive advantages; and, Hemostemix obtaining satisfactory financing to fund Hemostemix's operations including any research, trials or studies, and any Litigation. Forward-looking information is Subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of Hemostemix to be materially different from those expressed or implied by such forward-looking information. Such risks and other factors may include, but are not limited to: the ability of Hemostemix to complete clinical trials, complete a satisfactory analyses and file the results of such analyses to gain regulatory approval of a phase II or phase III clinical trial of ACP-01; potential litigation Hemostemix may face; general business, economic, competitive, political and social uncertainties; general capital market conditions and market prices for securities; delay or failure to receive board or regulatory approvals; the actual results of future operations including the actual results of future research, trials or studies; competition; changes in legislation affecting Hemostemix; the timing and availability of external financing on acceptable terms; long-term capital requirements and future developments in Hemostemix's markets and the markets in which it expects to compete; lack of qualified, skilled labour or loss of key individuals; and risks related to the COVID-19 pandemic including various recommendations, orders and measures of governmental authorities to try to limit the pandemic, including travel restrictions, border closures, non-essential business closures service disruptions, quarantines, self-isolations, shelters-in-place and social distancing, disruptions to markets, disruptions to economic activity and financings, disruptions to supply chains and sales channels, and a deterioration of general economic conditions including a possible national or global recession or depression; the potential impact that the COVID-19 pandemic may have on Hemostemix which may include a decreased demand for the services that Hemostemix offers; and a deterioration of financial markets that could limit Hemostemix's ability to obtain external financing. A description of additional risk factors that may cause actual results to differ materially from forward-looking information can be found in Hemostemix's disclosure documents on the SEDAR website at Although Hemostemix has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. Readers are cautioned that the foregoing list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Forward-looking information contained in this news release is expressly qualified by this cautionary statement. The forward-looking information contained in this news release represents the expectations of Hemostemix as of the date of this news release and, accordingly, it is Subject to change after such date. However, Hemostemix expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
4 days ago
- Yahoo
Financing Your Medical Degree at Texila American University in Guyana
GEORGETOWN, Guyana, June 16, 2025 /PRNewswire/ -- Texila American University (TAU) College of Medicine – Guyana today announced a significant expansion of its financial aid offerings, including official approval as a Sallie Mae partner school, dramatically increasing the accessibility of its accredited Doctor of Medicine (MD) program for students across North America and beyond. This initiative reinforces TAU's commitment to removing financial barriers for aspiring physicians seeking a world-class international medical education. U.S. Student Loan Programs – Sallie Mae Partnership Texila American University is now a Sallie Mae–approved institution, empowering eligible students to finance their medical education through private student loans. Sallie Mae® Medical School Loan for Future PhysiciansSallie Mae's Medical School Loan offers comprehensive financial support to help students in TAU's Doctor of Medicine (MD) program cover the full cost of attendance, including tuition, housing, books, and board preparation. Key benefits include: Up to 100% of education costs covered A 36-month grace period after graduation before repayment begins An extended 48-month residency deferment option Credit-based loan application for U.S. citizens and permanent residents And much more. Students can apply online directly with Sallie Mae, and TAU will certify the loan amount. Additionally, Sallie Mae offers a separate Residency and Relocation Loan of up to $30,000 to cover expenses related to interviews and relocation for residency. "Our mission is to cultivate the next generation of medical leaders, and that begins with accessibility," said TAU President Saju Bhaskar. "Our partnership with Sallie Mae is a monumental step forward, ensuring that talented and determined U.S. students have a clear and supportive financial route to achieving their MD at Texila. We believe that financial constraints should not stand in the way of a world-class medical education." Canadian Student Loan Options Texila American University is dedicated to supporting our Canadian students with multiple pathways to finance their education. Government Aid: OSAP Approved: Texila American University College of Medicine is an approved school for the Ontario Student Assistance Program (OSAP), providing access to loans and grants for eligible Ontario residents. Federal and Provincial Aid: All Canadian students are eligible to apply for federal aid through the Canada Student Financial Assistance Program. We also assist students with documentation for assistance from other provinces, such as British Columbia, Alberta, and Nova Scotia. Private Funding: Student Lines of Credit: Many central Canadian banks (including RBC, Scotiabank, TD, and BMO) offer professional student lines of credit up to CAD 200,000, often with interest-only payments during studies. Scholarship Opportunities TAU offers an extensive range of scholarships to reward academic excellence and support students from diverse backgrounds. These programs are competitive and available for eligible incoming students. Highlights include: Merit-Based: The Texila President Scholarship (full-tuition for Pre-Med) and the MCAT Scholarship (up to $1,000 per semester for high scores). Regional: The Global Citizen Grant (10-20% of MD tuition for non-Caribbean/Guyanese), CARICOM Scholarship (10-20% tuition), and Guyana Scholarship (up to 50% tuition). Specialized: The U.S. Military & Veteran Scholarship and the Medical Professional Scholarship, each offering up to $1,000 per semester. Please note: Students are typically eligible for only one scholarship at a time. The admissions committee is the final authority on all awards. "These comprehensive financial solutions empower students to focus on what truly matters: their education," remarked Dr. Hugh Duckworth, Provost. "Whether through Sallie Mae for our U.S. students, OSAP for Canadians in Ontario, or our diverse scholarship programs, we are building a supportive ecosystem. This allows students to confidently join our triple-accredited (CAAM-HP, ACCM, BAC) program, excel in their U.S. clinical rotations, and ultimately achieve success in U.S. residency placements." About Texila American University College of Medicine – Guyana TAU in Guyana offers a high-quality medical education designed to prepare graduates for global careers, particularly in the United States. As the only Caribbean medical school with CAAM-HP, ACCM, and BAC accreditations, TAU provides a quality-assured pathway to U.S. practice. Our graduates are ECFMG-eligible and benefit from a U.S.-aligned curriculum, U.S. clinical rotations in Arizona hospitals, and a proven 80% U.S. residency placement rate since 2015. With 4-year and 5.5-year MD programs, students learn on a diverse campus in Guyana featuring advanced labs and a supportive, international community from over 45 countries. This combination of accreditation, proven outcomes, and financial accessibility makes Texila American University a strong choice for students aiming to become successful doctors. For more information on enrollment, programs, or financial aid opportunities, please visit our website: If you have specific questions or would like to schedule a meeting, please email us at admissions@ Or Apply Now: Media Contact:Nisarg Patel, MD – Director of Admissions Ph: 1-732-226-2651 || Email: Texila American University College of Medicine – Guyana View original content to download multimedia: SOURCE Texila American University Sign in to access your portfolio
Business Wire
4 days ago
- Business Wire
Subway ® Canada's week-long Never Miss Lunch campaign asks Canadians to turn Cookies into Care
TORONTO--(BUSINESS WIRE)-- Subway Canada's annual Never Miss Lunch charitable campaign starts today, supporting children nationwide who are experiencing food insecurity. From now until June 22, every cookie purchased helps Food Banks Canada fill food packs with nutritious foods such as fruits, vegetables and dairy products, benefitting children in over 235 communities. 'No child should have to face the stress and uncertainty of hunger—especially during the summer months, when access to fresh food becomes more difficult for families,' says Kirstin Beardsley, CEO of Food Banks Canada. 'Thanks to dedicated partners like Subway, we can bridge that critical gap by providing access to nutritious and fresh foods for children throughout the country all summer long. Together, we're not only giving children food for fuel, we are also nurturing their potential and hope for a brighter future.' Now in its sixth year, the Subway Canada Never Miss Lunch program is proud to support Food Banks Canada, where donations will help distribute 215,000 food packs to children across hundreds of communities this summer. Since 2019, Subway Canada's Never Miss Lunch campaign has contributed to filling over one million nutritious food packs for children. As the exclusive Fresh Food Sponsor, Subway Canada plays a key role in ensuring that every pack includes not just shelf-stable items, but real, fresh food to fuel kids' bodies and minds. 'At Subway, we know that providing children with fresh, healthy food options and nourishing young minds and bodies is the first step towards giving kids the foundation to excel,' says Courtney Hindorff, Managing Director at Subway Canada. 'No child should have to start their day worried about where their next meal is coming from. With Never Miss Lunch, we're harnessing the power of community to put healthy, fresh foods within reach for kids—because supporting healthy futures starts with healthy, fresh meals.' Childhood food insecurity remains a pressing concern nationwide. According to Statistics Canada's most recent Canadian Income Survey, nearly 33% of all Canadian children under 18 live in households that struggle to afford enough food, amounting to approximately 2.5 million children facing hunger at home. To learn more, visit or follow along at @SubwayCanada. To find your nearest Subway restaurant, see here. * Subway ® will donate the equivalent of the average estimated net proceeds per cookie sold June 16-22, 2025 to Food Banks Canada. Guaranteed min. donation: $765K CAD for 2025. About Subway ® Restaurants With nearly 3,000 locations nationwide, Subway Canada is dedicated to serving freshly made sandwiches at great value to millions of guests. Subway restaurants are owned and operated by a network of dedicated Subway franchisees who are passionate about consistently delivering a high-quality, convenient guest experience and contributing positively to their local communities. Subway ® is a globally registered trademark of Subway IP LLC or one of its affiliates. © 2025 Subway. About Never Miss Lunch The Never Miss Lunch program is Subway ® Canada's commitment to children in communities across the country. In partnership with Food Banks Canada's After the Bell program, the initiative aims to provide nutritious food to kids in need during the summer break, when many community-based lunch programs end. As the exclusive Fresh Food Sponsor, Subway Canada provides fresh fruits and vegetables for food packs, which helps to ensure the packs are balanced and nutritious. Now in its 6th year, Subway ® Canada has helped Food Banks Canada deliver over one million food packs to hundreds of communities across Canada. About Food Banks Canada Food Banks Canada is the nation's leading force in the fight against hunger, advocating tirelessly for meaningful actions to counter food insecurity. With nearly 2 million visits to food banks monthly, on average, their mission is clear: to relieve hunger today and prevent it tomorrow. Collaborating with over 5,100 food banks and organizations nationwide, they invest in research, champion vital work, and work towards a Canada where no one goes hungry. Visit to learn more.
